Document Detail

Markers of thrombogenesis and fibrinolysis and their relation to inflammation and endothelial activation in patients with idiopathic pulmonary arterial hypertension.
Jump to Full Text
MedLine Citation:
PMID:  24312667     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Chronic anticoagulation is a standard of care in idiopathic pulmonary arterial hypertension (IPAH). However, hemostatic abnormalities in this disease remain poorly understood. Therefore, we aimed to study markers of thrombogenesis and fibrinolysis in patients with IPAH.
METHODS: We studied 27 consecutive patients (67% female) with IPAH aged 50.0 years (IQR: 41.0 - 65.0) and 16 controls without pulmonary hypertension. Prothrombin fragment 1+2 (F1+2) and thrombin-antithrombin (TAT) complexes were measured to assess thrombogenesis; tissue-type plasminogen activator (tPA) antigen and plasmin-anti-plasmin complex to characterize activation of fibrinolysis; plasminogen activator inhibitor 1 (PAI-1) to measure inhibition of fibrinolysis; and endothelin-1 (ET-1) and interleukin-6 (IL-6) to assess endothelial activation and systemic inflammation, respectively. In addition, in treatment-naive IPAH patients these markers were assessed after 3 months of PAH-specific therapies.
RESULTS: TPA (10.1[6.8-15.8] vs 5.2[3.3-7.3] ng/ml, p<0.001), plasmin-anti-plasmin (91.5[60.3-94.2] vs 55.8[51.1-64.9] ng/ml, p<0.001), IL-6 (4.9[2.5-7.9] vs 2.1[1.3-3.8] pg/ml, p=0.001) and ET-1 (3.7 [3.3-4.5] vs 3.4[3.1-3.5], p= 0.03) were higher in patients with IPAH than in controls. In IPAH patients plasmin-anti-plasmin and tPA correlated positively with IL-6 (r=0.39, p=0.04 and r=0.63, p<0.001, respectively) and ET-1 (r=0.55, p=0.003 and r=0.59, p=0.001, respectively). No correlation was found between tPA or plasmin-anti-plasmin and markers of thrombogenesis. Plasmin-anti-plasmin decreased after 3 months of PAH specific therapy while the other markers remained unchanged.
CONCLUSIONS: In the present study we showed that markers of fibrynolysis were elevated in patients with IPAH however we did not find a clear evidence for increased thrombogenesis in this group of patients. Fibrinolysis, inflammation, and endothelial activation were closely interrelated in IPAH.
Authors:
Grzegorz Kopeć; Deddo Moertl; Sabine Steiner; Ewa Stępień; Tomasz Mikołajczyk; Jakub Podolec; Marcin Waligóra; Jakub Stępniewski; Lidia Tomkiewicz-Pająk; Tomasz Guzik; Piotr Podolec
Related Documents :
23840807 - Permanent and transient congenital hypothyroidism in fayoum, egypt: a descriptive retro...
24274207 - Serum 25-hydroxyvitamin d levels are lower in chronic rhinosinusitis with nasal polypos...
23653897 - Cardioprotective effects of ω -3 pufas in chronic kidney disease.
24320627 - Value of maternal procalcitonin levels for predicting subclinical intra-amniotic infect...
6254457 - A trial of vidarabine for cytomegalovirus infection in renal transplant patients.
17546907 - Infective endocarditis at a tertiary care centre in saudi arabia: review of 47 cases ov...
Publication Detail:
Type:  Journal Article     Date:  2013-12-02
Journal Detail:
Title:  PloS one     Volume:  8     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2013  
Date Detail:
Created Date:  2013-12-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e82628     Citation Subset:  IM    
Affiliation:
Department of Cardiac and Vascular Diseases of the John Paul II Hospital in Krakow and the Jagiellonian University Collegium Medicum, Krakow, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
ISSN: 1932-6203
Publisher: Public Library of Science, San Francisco, USA
Article Information
Download PDF
Copyright: 2013 Kopeć et al
License:
Received Day: 15 Month: 7 Year: 2013
Accepted Day: 27 Month: 10 Year: 2013
collection publication date: Year: 2013
Electronic publication date: Day: 2 Month: 12 Year: 2013
Volume: 8 Issue: 12
E-location ID: e82628
PubMed Id: 24312667
ID: 3847115
Publisher Id: PONE-D-13-29155R2
DOI: 10.1371/journal.pone.0082628

Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension Alternate Title:Haemostasis Abnormalities in IPAH
Grzegorz Kopeć1*
Deddo Moertl2
Sabine Steiner3
Ewa Stępień4
Tomasz Mikołajczyk5
Jakub Podolec6
Marcin Waligóra1
Jakub Stępniewski1
Lidia Tomkiewicz-Pająk1
Tomasz Guzik5
Piotr Podolec1
James Westedit1 Role: Editor
1Department of Cardiac and Vascular Diseases of the John Paul II Hospital in Krakow and the Jagiellonian University Collegium Medicum, Krakow, Poland
2Department of Internal Medicine III (Cardiology and Emergency Medicine), Landesklinikum St. Poelten, St. Poelten, Austria
3Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
4Department of Clinical Biochemistry, Jagiellonian University Collegium Medicum, Krakow, Poland
5Department of Internal and Agricultural Medicine, Jagiellonian University Collegium Medicum, Krakow, Poland
6Department of Hemodynamics and Angiocardiography of the John Paul II Hospital in Krakow and the Jagiellonian University Collegium Medicum, Krakow, Poland
Vanderbilt University Medical Center, United States of America
Correspondence: * E-mail: gkopec@szpitaljp2.krakow.pl
[conflict] Competing Interests: The authors have declared that no competing interests exist.
Contributed by footnote: Conceived and designed the experiments: GK ES PP. Performed the experiments: GK ES JS LTP TG TM. Analyzed the data: GK SS DM MW ES TM. Contributed reagents/materials/analysis tools: GK JP. Wrote the manuscript: GK DM SS ES.

Introduction

Histopathological studies have shown a high prevalence of in situ thrombosis in patients with idiopathic pulmonary arterial hypertension (IPAH) [1,2]. Additionally, some observational studies suggested a survival benefit in patients with IPAH when taking oral anticoagulation [3]. Therefore, the use of vitamin K antagonists (VKA) has become a standard of care in IPAH [4].

This indication, however, has been questioned recently with the introduction of advanced PAH specific therapy which relieved many patients from bed resting [5,6]. Additionally, recent data suggested an increased bleeding risk in patients with IPAH compared to patients taking VKA for other reasons [7].

Generally, increased thrombotic or bleeding risk might stem from an altered balance between procoagulant, anticoagulant and fibrinolytic activity. The thrombin mediated enzymatic conversion of fibrinogen to fibrin is the major step in clot formation. Typically, in response to the generation of fibrin thrombus in vivo there is an activation of the fibrinolytic system [8]. Currently, the characteristics of these two counteracting processes in IPAH are poorly known.

Therefore, we aimed to characterize the process of thrombogenesis and fibrinolysis activation in patients with IPAH. As thrombogenesis and fibrinolysis in systemic circulation are interrelated with inflammation and endothelial function we also measured markers of inflammation and endothelial activation.


Methods
Study population

All study participants were recruited consecutively at the Department of Cardiac and Vascular Diseases at John Paul II Hospital in Krakow, Poland between July 2009 and November 2012 as shown in Figure 1.

Eligible patients were 1) patients with known IPAH scheduled for routine follow-up visit and 2) patients with suspected IPAH referred for diagnosis and management at our pulmonary hypertension (PH) centre. The latter group consisted of all patients, irrespectively of symptoms, in whom echocardiography showed increased right ventricular systolic pressure >40 mmHg [9] and in whom right heart catheterization was made in order to confirm or exclude the diagnosis of pulmonary hypertension. To be included in the study group secondary aetiologies of PH (liver disease, HIV infection, connective tissue disease, congenital heart defect, left heart disease, chronic thromboembolic disease and lung diseases) had to be excluded. Additional exclusion criteria were age ≤ 18 years, acute infection or apparent inflammatory process. Patients with mean pulmonary artery pressure (mPAP) ≥25mmHg and pulmonary artery wedge pressure (PAWP) ≤15 mmHg were diagnosed as IPAH. Patients with mPAP < 25 mmHg, PAWP ≤15mmHg, and a cardiac index (CI) ≥ 2.5 L/min/m2 were taken as controls. We considered the result of echocardiography (RVSP >40 mmHg) in the latter group as false positive. The institutional ethics committee (Komisja Bioetyczna przy Okręgowej Izbie Lekarskiej w Krakowie) approved the study protocol, and written informed consent was obtained from each patient before starting the study. All clinical investigations have been conducted according to the principles expressed in the Declaration of Helsinki.

Study protocol

Data on medical history, physical examination and laboratory parameters were obtained before cardiac catheterization. Patients with newly diagnosed IPAH were invited for a follow-up examination 3 months after initiation of PAH specific therapy. Cardiovascular risk factors were assessed according to current guidelines[10-14]. A smoker was defined as having smoked at least for one month during the previous 12 months; all others were classified as non-smokers. Body mass index was calculated as mass[kg]/height[m]2. Coronary angiography was performed in each patient to screen for coronary artery disease.

Cardiac catheterisation

Right heart catheterization (RHC) was performed in supine position from the right femoral vein access using a Swan-Ganz catheter in every patient. The acquisition of pressure waves was made at end expiration. Cardiac output was measured using the Fick oxygen consumption method. Blood oxygen saturation was measured with Co-oximeter OSM3 (Radiometer, Copenhagen, Denmark) while the oxygen consumption was estimated from the LaFarge equation as previously described [15]. Pulmonary vascular resistance was calculated as the difference between mPAP and PAWP divided by cardiac output.

Measurement of laboratory parameters

The venous blood samples were taken from each patient after an overnight fast in the morning on the day of catheterization. Additionally, in patients with newly diagnosed IPAH, repeat venous blood samples were taken three months after initiation of PAH specific therapy. Patients who were previously treated with VKA (only patients with prior diagnosis of IPAH) were switched to enoxaparine at least three days before RHC and had to have an INR < 1.2 when the blood was taken for further analysis. Patients did not receive enoxaparine in the morning of the day when blood samples were taken for analysis.

Blood samples were taken from the antecubital vein using sodium citrate (0,109 M) or EDTA as anti-coagulants as recommended by the manufacturer’s instructions for the assays and centrifuged within one hour after collection (2500 g, 20 min). Following the current recommendations [16] the second tube was used for the coagulation specimen. Plasma samples were stored in aliquots at −80°C. Immunoassays were performed according to manufacturers’ instructions.

Prothrombin fragment 1+2 (F1+2) and thrombin-antithrombin (TAT) complexes were measured to assess thrombogenesis. Tissue-type plasminogen activator (tPA) antigen and plasmin-anti-plasmin complex were measured to characterize activation of fibrinolysis. D-Dimer was chosen to reflect both processes. Plasminogen activator inhibitor 1 (PAI-1) was measured to assess inhibition of fibrinolysis. Endothelin-1 (ET-1) was used as a marker of endothelial activation, and interleukin-6 (IL-6) as a marker of chronic systemic inflammation.

F1+2 was assessed in citrate plasma with ELISA kit Human Prothrombin Fragment 1+2 (F1+2) (USCN Life Science Inc, TX, USA). TAT complexes concentrations were determined in citrate plasma by means of ELISA assay IMUBIND TAT ELISA (American diagnostica GmbH, Pfungstadt, Germany). TPA antigen levels were measured in citrate plasma by means of a one-step two-site immuno-assay Zymutest tPA antigen (BioMed, Neuville-sur-Oise, France). Plasmin-anti-plasmin complex concentrations were determined in citrate plasma by means of ELISA assay Plasmin-anti-plasmin Assay Kit (USCN Life Science Inc; Wuang, China). D-dimer levels were measured in citrate plasma by means of ELISA Zymutest D-dimer (Hyphen BioMed, Neuville-sur-Oise, France). PAI-1 levels were measured in citrate plasma by means of a one-step two-site immuno-assay Zymutest PAI-1 activity (Hyphen BioMed, Neuville-sur-Oise, France). The concentration of ET-1 was assessed in EDTA plasma by means of ELISA assay Human Endothelin-1 Quantikine (R&D Systems, MN, USA). The concentration of IL-6 was assessed in EDTA plasma by means of ELISA assay Human IL-6 Quantikine HS (R&D Systems, MN, USA).

Statistical analysis

Continuous variables were reported using median and interquartile range, categorical variables were described as counts and percentages. Patients with IPAH and controls were compared with the Mann Whitney U-test for the continuous variables and with the chi square test for categorical variables. The Wilcoxon rank sum test was used to compare parameters at baseline and after three months of treatment. Spearman rank correlation was used to assess the association between continuous variables. The significance level was set at p < 0.05. Statistical analysis was performed with Statistica PL software [StatSoft, Inc. (2010). STATISTICA (data analysis software system), version 9.1. Tulsa, USA www.statsoft.com] and MedCalc version 11.6.1.0 (MedCalc Software, Mariakerke, Belgium).


Results
Baseline characteristics

Among 234 patients who were assessed for eligibility (Figure 1), 191 patients were excluded due to other aetiologies of pulmonary hypertension (n=175), lack of informed consent (n=4), and missing hemodynamic criteria (n=12). The study population consisted of 43 participants: 27 patients with IPAH and 16 controls.

No differences in age and sex were found between patients and controls. At baseline, the majority of patients (n = 21; 78%) were treatment naive; the others were treated with sildenafil (2 patients), sildenafil and inhaled iloprost (1 patient), inhaled iloprost (1 patient), treprostinil s.c. with sildenafil (1 patient), and sitaxsentan (1 patient). After confirming the diagnosis of IPAH all drug-naive patients received PAH specific drugs: Fifteen patients were prescribed sildenafil, 2 verapamil, 1 inhaled iloprost, 1 sildenafil + inhaled iloprost and 2 subcutaneous treprostinil. Patient characteristics involving cardiovascular risk factors, cardiovascular drugs used before study enrolment and hemodynamic data are presented in Table 1. Seventeen (63%) IPAH patients were in WHO functional class III, 8 patients in functional class II and 2 patients in class IV at study entry. All but one IPAH patients and all controls had normal coronary arteries.

Twenty-one patients who were treatment naive at recruitment received PAH specific drug treatment after baseline measurements and were followed for 3 months. In 17 of these 21 patients we were able to reassess the laboratory markers after 3 months. From the remaining 4 patients 2 patients died during the follow up period, and 2 patients did not appear at the 3-months follow-up visit (Figure 1).

Markers of haemostasis, inflammation and endothelial dysfunction

Both markers of fibrinolysis, tPA and plasmin-anti-plasmin, were significantly higher in patients with IPAH than in controls (Table 2, Figure 2). In contrast, markers of thrombogenesis, TAT and F1+2, as well as PAI-1 and D-dimer did not differ between patients with IPAH and controls. IL-6 and ET-1 were higher in IPAH patients than in controls (Table 2, Figure 2). Similar results were obtained when only treatment naive IPAH patients were included in the analysis.

We did not observe a significant effect of previous treatment with VKA on the markers of thrombogenesis. F1+2 (76.0 [60.2-79.8] vs 73.7 [61.5-85.2], p =0.87) and TAT (8.7 [5.8-13.3] vs 8.4 [3.6-16.4], p=0.82) were similar in IPAH patients previously treated with VKA and those without prior VKA intake.

In previously drug-naive IPAH patients we observed a reduction of plasmin-anti-plasmin levels after 3 months of treatment with PAH specific drugs, while tPA, D-Dimer, TAT, F1+2, PAI-1, and IL-6, ET-1 remained unchanged (Table 3, Figure 3).

Correlations of tPA and plasmin-anti-plasmin in patients with IPAH

A positive correlation was found between tPA and plasmin-anti-plasmin and between tPA and PAI-1 (Table 4, Figure 4) in patients with IPAH. Furthermore, both plasmin-anti-plasmin and tPA correlated positively with IL-6 and ET-1, respectively (Table 4, Figure 4). No correlation was found between tPA or plasmin-anti-plasmin and markers of thrombogenesis (F1+2, TAT) while a non-significant trend for a positive correlation between tPA and F1+2 was observed. The analysis made after exclusion of the already treated IPAH patients confirmed the observations made on the whole study group. In the control group we found a positive correlation between tPA and PAI-1 (r=0.59, p=0.01), and fibrinogen (r=0.6, p=0.02), and between plasmin-anti-plasmin and fibrinogen (r=0.56, p=0.02).


Discussion

In the present study we have shown that markers of fibrinolysis were elevated in patients with IPAH while markers of thrombogenesis were not different from controls without PH. Furthermore, we found significant correlations between markers of fibrinolysis and both inflammation as well as endothelial activation indicating that these three distinct processes are interrelated in IPAH.

Current data on coagulation and the fibrinolytic systems in IPAH are inconsistent. Increased thrombin activity as measured by the level of circulating fibrinopeptide A was shown in one study [17]. However thrombin activity was not different between IPAH and controls in two other studies in which F1+2 and TAT were measured [18,19]. These data were published in 1990s and have not been reproduced in the modern era of pulmonary hypertension. However the changing demographics of IPAH population [20] and diagnostic criteria for this disease [4,21] limit extrapolation of such historical data to the current patient population.

Plasma markers of fibrinolysis such as tPA and plasmin-anti-plasmin were similar in PAH and controls in some studies [18,19] but elevated in other studies in patients with PAH associated with systemic sclerosis [8] and in women with IPAH [22]. Discrepant results were also shown for PAI-1 activity [18,19,23]. In our study, plasma levels of F1+2 and TAT complexes were similar in patients with IPAH and in controls suggesting lack of increased thrombin activation. In contrast, increased levels of tPA and plasmin-anti-plasmin complexes indicate increased fibrinolytic activity in IPAH. Activation of the fibrinolytic system – as observed in our study - does not necessarily contradict the high prevalence of thrombotic lesions found in autopsy studies of IPAH patients. A recent study has described fibrin that was resistant to lysis in patients with PH, suggesting that activated fibrinolysis might be ineffective to dissolve thrombi in the pulmonary vasculature [24]. On the other hand, activation of the fibrinolytic system could enhance the risk of bleeding. In fact, recent data from patients with PH treated with VKA demonstrated more major bleeding in IPAH and PAH associated with connective tissue disease than in CTEPH patients [7]. The authors of this study also reported a much higher rate of bleeding in this patient population than in large cohorts of patients treated with VKA for atrial fibrillation or venous thromboembolism [7].

Apart from thrombogenesis [25,26], other pathophysiologic stimuli of fibrinolysis have been described. In particular, endothelial activation and inflammation have been linked with haemostatic abnormalities in the systemic circulation [25,27,28]. Importantly, both endothelial activation and chronic inflammation have also been shown to play a significant role [29,30] in the development of IPAH.

High levels of the proinflammatory cytokine IL-6 have been reported in most [31] but not all [32] studies in IPAH. The increased IL-6 production in IPAH is thought to reflect enhanced synthesis by both inflammatory and pulmonary vascular cells [33]. In our study PAH specific therapies did not change plasma levels of IL-6 which confirmed findings from previous studies on IL-6 and some other inflammatory markers [34].

In animal models [35] pre-treatment with IL-6 induced a threefold increase of a basal tPA in the systemic circulation. In observational studies in various patient populations including healthy individuals, patients at high cardiovascular risk as well as in patients with advanced liver disease [36-39] IL-6 levels have been shown to correlate with tPA, which supports IL-6 induced endothelial cell activation and subsequent release of tPA as one of the potential underlying pathways [40]. In experimental models IL-6 also induced the expression of plasminogen, which is a substrate for plasmin [41]. Plasmin-anti-plasmin levels were shown to be increased in patients with chronic inflammatory disorders such as systemic sclerosis [8], systemic lupus erythematosus, arthritis and other forms of collagen diseases [42]. The weak correlation between tPA and plasmin-anti-plasmin levels in our study suggests that activation of some tPA independent pathways contributed to elevation of plasmin-anti-plasmin complex. Accordingly some authors [43] underscored that not only tPA but also urokinase type plasminogen activator (u-PA) and factor XII dependent pathways may play a major role in plasminogen activation in inflammatory diseases.

Endothelin-1 is a marker of endothelial dysfunction [43,44] and it has been shown to be involved in a spectrum of cardiovascular diseases ranging from coronary artery disease to PH. In our study ET-1 was increased in IPAH patients compared with controls and correlated positively with tPA and plasmin-anti-plasmin levels. This finding underscores endothelial cell activation in IPAH leading not only to the release of ET-1 but also plasminogen activators such as tPA or uPA, which further convert plasminogen to plasmin.

Of interest, in contrast to all other investigated markers, we found that the level of plasmin-anti-plasmin complex decreased after 3 months of PAH specific therapies. It was previously shown [45] that long-term prostacyclin infusion normalized platelet function and levels of endothelium derived clotting factors (factor VIII and von Willebrand factor). However, to the best of our knowledge, there are no published data showing the effects of PAH specific therapy on fibrinolytic markers. As plasmin-anti-plasmin complexes might reflect endothelial activation, it might be speculated that a reduction of their level reflects a beneficial effect of PAH specific therapy. The pathophysiological meaning and clinical consequence of this finding cannot be explained from our data and need further investigation.

Study limitations and strengths

We chose only a limited number of haemostatic markers, namely tPA, plasmin-anti-plasmin, TAT, F1+2, PAI-1 and D-Dimers, from a broad variety of potential parameters. The chosen ones, however, represent critical steps in thrombogenesis and fibrinolysis, which was our focus of interest. To evaluate endothelial activation and inflammation we measured only two markers, ET-1 and IL-6, however both have a well defined role in the pathogenesis of PH [30,46]. This study allows no insight into causal relationships between parameters of the hemostasis, endothelial dysfunction and inflammation, which would require an experimental approach.

The interruption of VKA before catheterization might have been too short to fully abolish VKA effects on parameters of thrombogenesis. However, we did not observe significant differences of F1.2 and TAT between VKA-treated and VKA–naive IPAH patients.

In this exploratory study we included a limited number of patients from one pulmonary hypertension centre. Therefore it is possible that some relevant associations could have been missed. Considering the low prevalence of IPAH in population a multicenter study involving large numbers of patients would be recommended to strengthen the validity of our results.

Strength of our study is the strictly defined IPAH population diagnosed according to current recommendations by international guidelines. Moreover, our data help in the search for the potential mechanisms underlying the recently observed increased bleeding risk in patients with IPAH.


Conclusions

In the present study we showed that markers of fibrinolysis were elevated in patients with IPAH however we did not find a clear evidence for increased thrombogenesis in this group of patients. Fibrinolysis, inflammation, and endothelial activation were closely interrelated in IPAH.

In the light of the increased bleeding risk in IPAH further large scale studies on the role of the specific abnormalities of haemostasis in IPAH patients are warranted.


References
1. Chaouat A,, Weitzenblum E,, Higenbottam T, (Year: 1996) The role of thrombosis in severe pulmonary hypertension. Eur Respir J9: 356-363.10.1183/09031936.96.09020356 PubMed: 87779778777977
2. Stacher E,, Graham BB,, Hunt JM,, Gandjeva A,, Groshong SD,et al. (Year: 2012) Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med186: 261-272.10.1164/rccm.201201-0164OC PubMed: 2267900722679007
3. Johnson SR,, Mehta S,, Granton JT, (Year: 2006) Anticoagulation in pulmonary arterial hypertension: A qualitative systematic review. Eur Respir J28: 999-1004.10.1183/09031936.06.00015206 PubMed: 1707491817074918
4. Galiè N,, Hoeper MM,, Humbert M,, Torbicki A,, Vachiery JL,et al. (Year: 2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the european respiratory society (ERS), endorsed by the international society of heart and lung transplantation (ISHLT). Eur Heart J30: 2493-2537.10.1093/eurheartj/ehp297 PubMed: 1971341919713419
5. Johnson SR,, Granton JT,, Tomlinson GA,, Grosbein HA,, Le T,et al. (Year: 2012) Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A bayesian approach to evaluating treatment for uncommon disease. J Rheumatol39: 276-285.10.3899/jrheum.110765 PubMed: 2224735322247353
6. Peacock A, (Year: 2013) Pulmonary hypertension. Eur Respir Rev22: 20-25.10.1183/09059180.00006912 PubMed: 2345716023457160
7. Henkens IR,, Hazenoot T,, Boonstra A,, Huisman MV,, Vonk-Noordegraaf A, (Year: 2013) Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J41: 872-878.10.1183/09031936.00039212 PubMed: 2293670422936704
8. Jinnin M,, Ihn H,, Yamane K,, Asano Y,, Yazawa N,et al. (Year: 2003) Plasma plasmin-alpha2-plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension. Rheumatology (Oxford)42: 240-243.10.1093/rheumatology/keg071 PubMed: 1259561712595617
9. McLaughlin VV,, Archer SL,, Badesch DB,, Barst RJ,, Farber HW,et al. (Year: 2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the american college of cardiology foundation task force on expert consensus documents and the american heart association developed in collaboration with the american college of chest physicians; american thoracic society, inc.; and the pulmonary hypertension association. J Am Coll Cardiol53: 1573-1619.10.1016/j.jacc.2009.01.004 PubMed: 1938957519389575
10. Kozek E,, Podolec P,, Kopeć G,, Pajak A,, Tykarski A,et al. (Year: 2008) Polish forum for prevention guidelines on diabetes. Kardiol Pol66: 1020-1023 PubMed: 1900411919004119
11. Kawecka-Jaszcz K,, Jankowski P,, Podolec P,, Kopeć G,, Naruszewicz M,et al. (Year: 2008) Polish forum for prevention guidelines on smoking. Kardiol Pol66: 125-126.10.1140/epjb/e2008-00381-8 PubMed: 1836322718363227
12. Cybulska B,, Szostak WB,, Podolec P,, Kopeć G,, Naruszewicz M,et al. (Year: 2008) Polish forum for prevention guidelines on dyslipidaemia. Kardiol Pol66: 1239-1242 PubMed: 1910510619105106
13. Tykarski A,, Podolec P,, Kopeć G,, Pajak A,, Kawecka-Jaszcz K,et al. (Year: 2007) Polish forum for prevention guidelines on arterial hypertension. Kardiol Pol65: 1137-1141 PubMed: 1826881718268817
14. Zahorska-Markiewicz B,, Podolec P,, Kopeć G,, Drygas W,, Godycki-Cwirko M,et al. (Year: 2008) Polish forum for prevention guidelines on overweight and obesity. Kardiol Pol66: 594-596 PubMed: 1863039418630394
15. LaFarge CG,, Miettinen OS, (Year: 1970) The estimation of oxygen consumption. Cardiovasc Res4: 23-30.10.1093/cvr/4.1.23 PubMed: 54168405416840
16. Lippi G,, Franchini M,, Montagnana M,, Salvagno GL,, Poli G,et al. (Year: 2006) Quality and reliability of routine coagulation testing: Can we trust that sample?Blood Coagul Fibrinolysis17: 513-519.10.1097/01.mbc.0000245290.57021.46 PubMed: 1698854416988544
17. Eisenberg PR,, Lucore C,, Kaufman L,, Sobel BE,, Jaffe AS,et al. (Year: 1990) Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation82: 841-847.10.1161/01.CIR.82.3.841 PubMed: 23940052394005
18. Welsh CH,, Hassell KL,, Badesch DB,, Kressin DC,, Marlar RA, (Year: 1996) Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest110: 710-717.10.1378/chest.110.3.710 PubMed: 87974168797416
19. Hoeper MM,, Sosada M,, Fabel H, (Year: 1998) Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J12: 1446-1449.10.1183/09031936.98.12061446 PubMed: 98775079877507
20. Ling Y,, Johnson MK,, Kiely DG,, Condliffe R,, Elliot CA,et al. (Year: 2012) Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: Results from the pulmonary hypertension registry of the united kingdom and ireland. Am J Respir Crit Care Med186: 790-796.10.1164/rccm.201203-0383OC PubMed: 2279832022798320
21. Rich S,, Dantzker DR,, Ayres SM,, Bergofsky EH,, Brundage BH,et al. (Year: 1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med107: 216-223.10.7326/0003-4819-107-2-216 PubMed: 36059003605900
22. Christ G,, Graf S,, Huber-Beckmann R,, Zorn G,, Lang I,et al. (Year: 2001) Impairment of the plasmin activation system in primary pulmonary hypertension: Evidence for gender differences. Thromb Haemost86: 557-562 PubMed: 1152200311522003
23. Huber K,, Beckmann R,, Frank H,, Kneussl M,, Mlczoch J,et al. (Year: 1994) Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med150: 929-933.10.1164/ajrccm.150.4.7921465 PubMed: 79214657921465
24. Miniati M,, Fiorillo C,, Becatti M,, Monti S,, Bottai M,et al. (Year: 2010) Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic. Am J Respir Crit Care Med181: 992-996.10.1164/rccm.200907-1135OC PubMed: 2007538620075386
25. Cesarman-Maus G,, Hajjar KA, (Year: 2005) Molecular mechanisms of fibrinolysis. Br J Haematol129: 307-321.10.1111/j.1365-2141.2005.05444.x PubMed: 1584265415842654
26. Emeis JJ, (Year: 1992) Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products. Ann N Y Acad Sci667: 249-258.10.1111/j.1749-6632.1992.tb51622.x PubMed: 13090431309043
27. van Hinsbergh VW, (Year: 2012) Endothelium--role in regulation of coagulation and inflammation. Semin Immunopathol34: 93-106.10.1007/s00281-011-0285-5 PubMed: 2184543121845431
28. Levi M,, van der Poll T,, Büller HR, (Year: 2004) Bidirectional relation between inflammation and coagulation. Circulation109: 2698-2704.10.1161/01.CIR.0000131660.51520.9A PubMed: 1518429415184294
29. Budhiraja R,, Tuder RM,, Hassoun PM, (Year: 2004) Endothelial dysfunction in pulmonary hypertension. Circulation109: 159-165.10.1161/01.CIR.0000102381.57477.50 PubMed: 1473450414734504
30. Price LC,, Wort SJ,, Perros F,, Dorfmuller P,, Huertas A,et al. (Year: 2012) Inflammation in pulmonary arterial hypertension. Chest141: 210-221.10.1378/chest.11-0793 PubMed: 2221582922215829
31. Soon E,, Holmes AM,, Treacy CM,, Doughty NJ,, Southgate L,et al. (Year: 2010) Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation122: 920-927.10.1161/CIRCULATIONAHA.109.933762 PubMed: 2071389820713898
32. Hiremath J,, Thanikachalam S,, Parikh K,, Shanmugasundaram S,, Bangera S,et al. (Year: 2010) Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial. J Heart Lung Transplant29: 137-149.10.1016/j.healun.2009.09.005 PubMed: 2002226420022264
33. Savale L,, Tu L,, Rideau D,, Izziki M,, Maitre B,et al. (Year: 2009) Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res10: 6-9921-10-6 PubMed: 1917374019173740
34. Damås JK,, Otterdal K,, Yndestad A,, Aass H,, Solum NO,et al. (Year: 2004) Soluble CD40 ligand in pulmonary arterial hypertension: Possible pathogenic role of the interaction between platelets and endothelial cells. Circulation110: 999-1005.10.1161/01.CIR.0000139859.68513.FC PubMed: 1530279415302794
35. Kruithof EK,, Mestries JC,, Gascon MP,, Ythier A, (Year: 1997) The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6. Thromb Haemost77: 905-910 PubMed: 91844019184401
36. Wannamethee SG,, Sattar N,, Rumley A,, Whincup PH,, Lennon L,et al. (Year: 2008) Tissue plasminogen activator, von willebrand factor, and risk of type 2 diabetes in older men. Diabetes Care31: 995-1000.10.2337/dc07-1569 PubMed: 1823505418235054
37. Yudkin JS,, Stehouwer CD,, Emeis JJ,, Coppack SW, (Year: 1999) C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue?Arterioscler Thromb Vasc Biol19: 972-978.10.1161/01.ATV.19.4.972 PubMed: 1019592510195925
38. Wannamethee SG,, Whincup PH,, Rumley A,, Lowe GD, (Year: 2007) Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J Thromb Haemost5: 1637-1643.10.1111/j.1538-7836.2007.02643.x PubMed: 1759614017596140
39. Páramo JA,, Sangro B,, Prósper F,, Quiroga J,, Rifón J,et al. (Year: 1995) Increased concentrations of tumor necrosis factor and interleukin-6 contribute to the hemostatic abnormalities in advanced liver disease. Haemostasis25: 305-311 PubMed: 85863228586322
40. Kerr R,, Stirling D,, Ludlam CA, (Year: 2001) Interleukin 6 and haemostasis. Br J Haematol115: 3-12.10.1046/j.1365-2141.2001.03061.x PubMed: 1172240311722403
41. Jenkins GR,, Seiffert D,, Parmer RJ,, Miles LA, (Year: 1997) Regulation of plasminogen gene expression by interleukin-6. Blood89: 2394-2403 PubMed: 91162839116283
42. Kawakami M,, Kawagoe M,, Harigai M,, Hara M,, Hirose T,et al. (Year: 1989) Elevated plasma levels of alpha 2-plasmin inhibitor-plasmin complex in patients with rheumatic diseases. possible role of fibrinolytic mechanism in vasculitis. Arthritis Rheum32: 1427-1433.10.1002/anr.1780321112 PubMed: 25309902530990
43. Paulus P,, Jennewein C,, Zacharowski K, (Year: 2011) Biomarkers of endothelial dysfunction: Can they help us deciphering systemic inflammation and sepsis?Biomarkers16Suppl 1: S11-S21.10.3109/1354750X.2011.587893 PubMed: 2170744021707440
44. Abraham D,, Dashwood M., (Year: 2008) Endothelin--role in vascular disease. Rheumatology (Oxford)47Suppl 5: v23-4..
45. Friedman R,, Mears JG,, Barst RJ, (Year: 1997) Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation96: 2782-2784.10.1161/01.CIR.96.9.2782 PubMed: 93861379386137
46. Davie NJ,, Schermuly RT,, Weissmann N,, Grimminger F,, Ghofrani HA, (Year: 2009) The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: Current understanding and future studies. Eur J Clin Invest39Suppl 2: 38-49.10.1111/j.1365-2362.2009.02120.x PubMed: 1933574619335746

Figures

[Figure ID: pone-0082628-g001]
doi: 10.1371/journal.pone.0082628.g001.
Figure 1  Study flow chart explaining selection of participants of the study and depicting the follow-up scenario.

CI, cardiac index; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure.



[Figure ID: pone-0082628-g002]
doi: 10.1371/journal.pone.0082628.g002.
Figure 2  Comparison of hemostatic markers, Interleukin-6, and Endothelin-1 between patients with idiopathic arterial hypertension and controls.

ET-1 - endothelin 1, F1+2 - prothrombin fragments 1+2, IL-6 - Interleukin 6, PAI-1 - plasminogen activator inhibitor 1, TAT - thrombin-antithrombin, tPA - tissue plasminogen activator. In this box-and-whisker plot, the central box represents the values from the lower to upper quartile (25 to 75 percentile). The middle line represents the median. A line extends from the minimum to the maximum value, excluding values that are smaller than the lower quartile minus 1.5 times the interquartile range, or larger than the upper quartile plus 1.5 times the interquartile range.



[Figure ID: pone-0082628-g003]
doi: 10.1371/journal.pone.0082628.g003.
Figure 3  Levels of haemostatic variables, Interleukin-6 and Endothelin-1 at baseline and after 3 months of pulmonary arterial hypertension specific therapy.

ET-1 - endothelin-1, F1+2 - prothrombin fragments 1+2, IL-6 - interleukin 6, PAI-1 - plasminogen activator inhibitor, TAT - thrombin-anti-thrombin, tPA- tissue plasminogen activator.



[Figure ID: pone-0082628-g004]
doi: 10.1371/journal.pone.0082628.g004.
Figure 4  Significant correlations between hemostatic markers, Endothelin-1, and Interleukin-6.

ET-1 - Endothelin -1, IL-6 - Interleukin 6, PAI-1 - PAI-1 - plasminogen activator inhibitor 1, tPA - tissue plasminogen activator.



Tables
[TableWrap ID: pone-0082628-t001] Table 1  Patient characteristics.
Variable IPAH (n=27) Controls (n=16) P
Age [years] 50.0 (41.0-65.0) 54.0 (37.0-60.5) 0.76
Sex [males] 9 (33%) 5 (31%) 0.84
BMI [kg/m2] 23.0 (21.0-26.0) 27.3 (22.3-28.3) 0.02
Total cholesterol [mmol/l] 4.1 (3.6-4.7) 4.7 (4.6-5.3) 0.007
LDL-cholesterol [mmol/l] 2.4 (1.7-2.8) 2.7 (2.5-3.5) 0.03
HDL-cholesterol [mmol/l] 1.3 (1.1-1.5) 1.6 (1.3-1.8) 0.01
Triglycerides [mmol/l] 1.0 (0.8-1.4) 1.1 (0.9-1.4) 0.7
Diabetes 4 (15%) 0 0.28
Systemic arterial hypertension 10 (37%) 8 (50%) 0.61
Smoking 0 0 -
hsCRP [mg/dl] 2.4 (1.2-8.2) 1.1 (0.7-2.2) 0.004
Creatinine [umol/l] 80.0 (73.0-98.0) 68.5 (59.0-88.5) 0.02
Drugs taken before entering the study
Statins 9 (33%) 6 (38%) 0.96
Diuretics 12 (44%) 0 0.005
ACEI 6 (22%) 6 (38%) 0.47
Beta blockers 8 (30%) 6 (38%) 0.80
CCB 8 (30%) 2 (12.5%) 0.36
Vitamin K antagonist* 6 0 -
Hemodynamic data
PA mean pressure [mmHg] 54.0 (44.3-66.3) 11.0 (9.5-13.0) <0.001
RA pressure [mmHg] 8.0 (5.0-13.0) 2.0 (2.0-3.0) <0.001
PAW mean pressure [mmHg] 8.0 (4.5-11.3) 7.5 (5.5-9.0) 0.36
Ao mean pressure [mmHg] 90.0 (79.0-96.8) 100.0 (94.0-102.0) 0.02
Cardiac index [l/min/m2] 1.6 (1.4-1.9) 2.7 (2.7-2.8) <0.001
Estimated oxygen consumption (ml/min) 187.5 (176.2-203.1) 180.6 ( 160.9 - 270.6) 0.58
PVR [WU] 15.9 (11.3-20.9) 0.7 (0.4-1.3) <0.001

*only patients with known IPAH were treated with vitamin K antagonists before enrolment to the study

ACEI - angiotensin converting enzyme inhibitor, BMI - body mass index, CCB - calcium channel blockers, HDL - high density lipoprotein, LDL - low density lipoprotein, PA - pulmonary artery, PAW - pulmonary artery wedge, PVR - pulmonary vascular resistance, RA - right atrium, WU - Wood Units


[TableWrap ID: pone-0082628-t002] Table 2  Markers of hemostasis, Interleukin-6 and Endothelin-1 in patients with IPAH and controls.
Parameter IPAH (n=27) Controls (n=16) P
tPA [ng/ml] 10.1 (6.8-15.8) 5.2 (3.3-7.3) <0.001
Plasmin-anti-plasmin [ng/ml] 91.5 (60.3-94.2) 55.8 (51.1-64.9) <0.001
TAT (ng/ml) 8.7 (4.5-14.9) 8.2 (4.9-22.2) 0.8
F1+2 (ng/ml) 73.9 (59.7-84.4) 71.8 (63.5-78.9) 0.92
PAI-1 (ng/ml) 0.58 (0.1-1.4) 0.46 (0.2-1.5) 0.94
Fibrinogen (g/l) 3.1 (2.7-3.7) 3.2 (2.8-3.5) 0.86
D-dimer (ng/ml) 342.8 (243.1-648.9) 513.4 (263.5-732.7) 0.56
Il-6 (pg/ml) 4.9 (2.5-7.9) 2.1 (1.3-3.8) 0.001
ET-1 (pg/ml) 3.7 (3.3-4.5) 3.4 (3.1-3.5) 0.03

ET-1 - endothelin-1, F1+2 - prothrombin fragments 1+2, IL-6 - interleukin 6, tPA- tissue plasminogen activator, PAI-1 - plasminogen activator inhibitor, TAT - thrombin-anti-thrombin


[TableWrap ID: pone-0082628-t003] Table 3  Median change of markers of hemostasis, Interleukin-6, and Endothelin-1 after 3 months of PAH specific treatment in patients who were treatment naive at study entry.
Parameter Median (IQR) P
tPA [ng/ml] 0.01 (-5.1 - 4.9) 0.96
Plasmin-anti-plasmin [ng/ml] -2.9 (-5.6 - -0.2) 0.02
TAT (ng/ml) -0.7 (-5.9 - 12.9) 0.8
F1+2 (ng/ml) 9.0 (-4.2 - 19.5) 0.27
PAI-1 (ng/ml) 0.09 (-0.9 - 0.5) 0.78
D-Dimer (ng/ml) 6.2 (-326.4 - 67.1) 0.46
Il-6 (pg/ml) 0.6 (-2.3 - 3.0) 0.49
ET-1 (pg/ml) -0.2 (-1.0 -0.4) 0.31

ET-1 - endothelin-1, F1+2 - prothrombin fragments 1+2, IL-6 - interleukin 6, IQR - interquartile range, tPA- tissue plasminogen activator, PAI-1 - plasminogen activator inhibitor, TAT - thrombin-anti-thrombin


[TableWrap ID: tab4] Table 4  Correlations between tPA and plasmin-anti-plasmin and other haemostatic variables, Endothelin-1 and Interleukin-6 in patients with IPAH.
tPA
Plasmin-anti-plasmin
r P r P
Plasmin-anti-plasmin [ng/ml] 0.4 0.01 - -
TAT (ng/ml) 0.1 0.64 0.03 0.86
F1+2 (ng/ml) -0.38 0.06 -0.3 0.12
PAI-1 (ng/ml) 0.44 0.03 0.29 0.13
D-Dimer (ng/ml) 0.34 0.09 0.02 0.93
Fibrinogen -0.01 0.68 -0.1 0.64
Il-6 0.63 <0.001 0.39 0.04
ET-1 0.59 0.001 0.55 0.003

ET-1 - endothelin-1, F1+2 - prothrombin fragments 1+2, IL-6 - interleukin 6, tPA- tissue plasminogen activator, PAI-1 - plasminogen activator inhibitor, TAT - thrombin-anti-thrombin



Article Categories:
  • Research Article


Previous Document:  Phenotypic convergence in genetically distinct lineages of a rhinolophus species complex (mammalia, ...
Next Document:  Rates of fetal polydrug exposures in methadone-maintained pregnancies from a high-risk population.